ArticleBMC gastroenterology2025
Efficacy and safety of reduced thromboprophylaxis with low molecular weight heparin for hepatocellular carcinoma after conversion therapy.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTyrosine kinase inhibitors (TKIs) impairs factor Xa (FXa)-mediated coagulation. This study aims to assess the safety and feasibility of reduced thromboprophylaxis with low molecular weight heparin (LMWH) for hepatocellular carcinoma (HCC) converted by Lenvatinib treatment.
methodsOne hundred forty consecutive HCC patients who received Lenvatinib standalone therapy before hepatectomy were retrospectively enrolled. Group A received reduced LMWH (≤ 100 IU/kg daily for ≤ 5 days), while Group B received no pharmacologic thromboprophylaxis. Primary outcome was incidence of thrombotic or hemorrhagic complications. Secondary outcome was overall survival (OS).
resultsSixty-two and seventy-four patients were divided into group A and B respectively. The incidence of VTE (4.8% vs. 14.9%, P = 0.091, OR = 0.31, 95% CI: 0.08-1.16) and postoperative hemorrhage (3.2% vs. 9.5%, P = 0.298, OR = 0.34, 95% CI: 0.07-1.69) trended lower in Group A.
conclusionLimitations include a retrospective design, potential selection bias, and limited statistical power. Our findings suggest a trend toward reduced hemorrhagic and thrombotic risks with reduced LMWH, though statistical significance was not reached (VTE P = 0.091, hemorrhage P = 0.298) reduce such risks in HCC patients after neoadjuvant Lenvatinib and hepatectomy, though limitations like the retrospective design should be noted. Clinically, reduced LMWH prophylaxis offers a safe alternative for high-bleeding-risk patients, guiding surgical teams to balance thrombosis-bleeding risks and informing oncologists' perioperative anticoagulation strategies.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.